361 related articles for article (PubMed ID: 26313697)
1. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of clindamycin phosphate and benzoyl peroxide gel (DUAC(®) ) in the treatment of EGFR inhibitors-associated acneiform eruption.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Eur Acad Dermatol Venereol; 2016 Aug; 30(8):1436-8. PubMed ID: 26290481
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
Tsutsui K; Kikuchi K; Nozawa K; Takashima A; Tsuchiyama K; Namikawa K; Aiba S; Yamazaki N
J Dermatol; 2021 Jul; 48(7):1077-1080. PubMed ID: 33682955
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea.
Breneman D; Savin R; VandePol C; Vamvakias G; Levy S; Leyden J
Int J Dermatol; 2004 May; 43(5):381-7. PubMed ID: 15117375
[TBL] [Abstract][Full Text] [Related]
5. Comparative Trial of Silver Nanoparticle Gel and 1% Clindamycin Gel when Use in Combination with 2.5% Benzoyl Peroxide in Patients with Moderate Acne Vulgaris.
Jurairattanaporn N; Chalermchai T; Ophaswongse S; Udompataikul M
J Med Assoc Thai; 2017 Jan; 100(1):78-85. PubMed ID: 29911775
[TBL] [Abstract][Full Text] [Related]
6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
7. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
8. Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Aqueous Gel: Long-Term Use in Adult Females With Moderate Acne Vulgaris.
Kircik LH
J Drugs Dermatol; 2017 Jun; 16(6):543-546. PubMed ID: 28686771
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations.
Webster G; Rich P; Gold MH; Mraz S; Calvarese B; Chen D
J Drugs Dermatol; 2009 Aug; 8(8):736-43. PubMed ID: 19663111
[TBL] [Abstract][Full Text] [Related]
10. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
[TBL] [Abstract][Full Text] [Related]
11. Clindamycin phosphate 1·2%-benzoyl peroxide 3·0% fixed-dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single-blinded, active-controlled, parallel-group study.
Kawashima M; Hashimoto H; Alió Sáenz AB; Ono M; Yamada M
Br J Dermatol; 2015 Feb; 172(2):494-503. PubMed ID: 25040180
[TBL] [Abstract][Full Text] [Related]
12. Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption.
Park JH; Choi Y; Kim HJ; Oh SJ; Lee DY; Lee JH; Lee JH
Dermatology; 2021; 237(3):457-463. PubMed ID: 33302268
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
[TBL] [Abstract][Full Text] [Related]
14. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial.
Kellett N; West F; Finlay AY
Br J Dermatol; 2006 Mar; 154(3):524-32. PubMed ID: 16445786
[TBL] [Abstract][Full Text] [Related]
15. Fitzpatrick skin types and clindamycin phosphate 1.2%/benzoyl peroxide gel: efficacy and tolerability of treatment in moderate to severe acne.
Callender VD
J Drugs Dermatol; 2012 May; 11(5):643-8. PubMed ID: 22527435
[TBL] [Abstract][Full Text] [Related]
16. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
17. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
18. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris.
Pariser DM; Rich P; Cook-Bolden FE; Korotzer A
J Drugs Dermatol; 2014 Sep; 13(9):1083-9. PubMed ID: 25226009
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
20. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
[No Abstract] [Full Text] [Related]
[Next] [New Search]
